Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
Sparrow BioAcoustics [Sparrow], a pioneer in the field of bioacoustics technology, announces the launch of Stethophone™, a groundbreaking advancement in personalized heart health, exclusively on Valentine’s Day, February 14, 2024.
Theseus Pharmaceuticals, Inc. today announced that Concentra Biosciences, LLC (“Concentra”) through its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4.05 in cash.
Theseus Pharmaceuticals Announces Closing of Tender Offer Read More »
YS Biopharma Co., Ltd. today announced the appointment of six new members to its Board of Directors (the “Board”), effective February 13, 2024.
YS Biopharma Announces Appointment of New Directors Read More »
Two weeks after Vertex’s Phase III data for VX-548 reenergized the field, Latigo Biotherapeutics announced $135 million in Series A funds to push its own NaV1.8 inhibitor into Phase II.
Latigo Launches into Non-Opioid Pain Medicine Space with $135 Million Series A Read More »
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2023 on Tuesday, Feb. 20 at 9 a.m., ET.
En lo profundo del corazón de Quebec, Canadá, yace un misterio geológico que ha fascinado a científicos y aventureros durante décadas: el Cráter Manicouagan. Este impresionante cráter de impacto, con un diámetro de aproximadamente 100 kil&oacut …
Beactica Therapeutics AB announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2024.
Immunome, Inc., a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share.
Immunome Announces Pricing of Public Offering of Common Stock – February 14, 2024 Read More »
Los edificios antiguos son testigos silenciosos de la historia, recordándonos el ingenio y la habilidad de las civilizaciones que vinieron antes que nosotros. Desde las pirámides de Egipto hasta las antiguas ciudades de Mesopotamia, veamos algunos de los edificios más antiguos d …
Los edificios más antiguos del mundo que resistieron el paso del tiempo Read More »
